Severina I S
Biomed Khim. 2005;51(1):19-29.
The paper reviews the main approaches used for development of effective therapeutic means directly regulating signaling system "nitric oxide (NO)--soluble guanylate cyclase--cyclic guanosine monophosphate (cGMP)". Special attention is paid to the role of this system in the mechanism of action of so called "old drugs". Using new approaches for investigating the antihypertensive and anti-aggregatory action of NO and the role of guanylate cyclase in these processes the priority and fundamental data concerning the elaboration of the molecular basis of directed search and creation of new, effective antihypertensive and antiaggregatory compounds have been obtained. Studies of direct activation of soluble guanylate cyclase by the original NO-donors new activators of this enzyme resulted in discovery of new drugs participating in regulation of haemostasis and vascular tone. The priority data on new inhibitors of NO-dependent activation of guanylate cyclase (among which turn to the drugs) and the possible molecular mechanism of their pharmacological action are presented. It was shown at first time that the signaling system "NO-soluble guanylate cyclase-cGMP" may be involved in the mechanism of the therapeutic action of a number of widely used drugs including those acting as chemotherapeutics and antiprotozoics.
本文综述了直接调节“一氧化氮(NO)-可溶性鸟苷酸环化酶-环磷酸鸟苷(cGMP)”信号系统以开发有效治疗手段的主要方法。特别关注了该系统在所谓“老药”作用机制中的作用。通过研究NO的降压和抗聚集作用以及鸟苷酸环化酶在这些过程中的作用的新方法,获得了有关定向搜索和创建新型有效降压和抗聚集化合物分子基础的重要且基础的数据。对新型NO供体直接激活可溶性鸟苷酸环化酶(该酶的新型激活剂)的研究导致发现了参与止血和血管张力调节的新药。介绍了关于NO依赖性鸟苷酸环化酶激活的新型抑制剂(其中包括转向药物)的重要数据及其药理作用的可能分子机制。首次表明,“NO-可溶性鸟苷酸环化酶-cGMP”信号系统可能参与了许多广泛使用的药物(包括用作化疗药物和抗原生动物药物)的治疗作用机制。